Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.
By J. Wei, Rodney L Dunn, M. Litwin, H. Sandler, M. Sanda. Urology, 2000
1,465 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine, Urology
View Paper: https://www.semanticscholar.org/paper/511662e8ca34c3b1b40564d67b4ff00df7b2eab0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- D. Penson
- A. Hamilton
- P. Albertsen
- R. Van Horn
- K. Fan
- R. Hoffman
- M. Goodman
- T. Koyama
Citations in the corpus
- Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. (2017, neutral): “15 42 (7) 41 (7) PSA, ng/mL , 5 103 (17) 116 (19) 5-10 302 (50) 303 (51) 10.”
- Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer (2013, methodology): “We measured disease-specific health-related quality of life using items adapted from previously validated and reliable instruments.(11-14) Multi-item rating scales were summarized as a binary measure to facilitate clinical interpretation regarding urinary incontinence, bowel function, and sexual fun”